GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Net Income From Continuing Operations

Beijing Luzhu Biotechnology Co (HKSE:02480) Net Income From Continuing Operations : HK$-272.73 Mil (TTM As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Beijing Luzhu Biotechnology Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Beijing Luzhu Biotechnology Co's net income from continuing operations for the six months ended in Jun. 2023 was HK$-86.79 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-272.73 Mil.

Beijing Luzhu Biotechnology Co Net Income From Continuing Operations Historical Data

The historical data trend for Beijing Luzhu Biotechnology Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Luzhu Biotechnology Co Net Income From Continuing Operations Chart

Beijing Luzhu Biotechnology Co Annual Data
Trend Dec21 Dec22 Dec23
Net Income From Continuing Operations
-660.43 -809.82 -272.73

Beijing Luzhu Biotechnology Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
Net Income From Continuing Operations - -764.37 -81.63 -86.79 -185.94

Beijing Luzhu Biotechnology Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-272.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beijing Luzhu Biotechnology Co (HKSE:02480) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Beijing Luzhu Biotechnology Co Ltd (HKSE:02480) » Definitions » Net Income From Continuing Operations
Comparable Companies
HKSE:00775 HKSE:02696 HKSE:02157 HKSE:06855 HKSE:02171 HKSE:02487 HKSE:06955 HKSE:02315 HKSE:02105 HKSE:02179 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 3 Guangtong Street, Industrial Development Zone, Zhangjiawan Tongzhou District, Beijing, CHN
Website
http://www.luzhubiotech.com
Beijing Luzhu Biotechnology Co Ltd is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Its clinical-stage product candidates comprise one vaccine candidate, LZ901 and two antibody injection product candidates, including K3 and K193. LZ901 is our Core Product.

Beijing Luzhu Biotechnology Co (HKSE:02480) Headlines

No Headlines